Laser treatment clinical trial misses primary endpoint

February 20, 2009

Using a laser to treat cells in the brain did not significantly reduce stroke disability, according to results of the first major clinical trial of laser therapy presented at the American Stroke Association's International Stroke Conference 2009.

The full study will be simultaneously published in Stroke: Journal of the American Heart Association and is presented in the "Sample of the Best Science of the ISC" session during the conference.

Researchers said the laser's impact on stroke disability did not reach statistical significance for the overall group of stroke patients. However, it appeared that laser therapy did provide some improvement in those experiencing moderate to moderately severe strokes.

"Although our primary endpoint of improvement for overall stroke disability missed reaching statistical significance, we saw no ill effects from the laser treatment. And, in fact, there was a strong signal that this treatment actually offered some improvement for patients with moderate to moderately severe strokes, even in the presence of prior risk factors such as previous stroke, heart disease and diabetes," said Justin Zivin, M.D. Ph.D., principal investigator of the study and a professor of neurosciences at the University of California San Diego.

The NeuroThera Effectivess and Safety Trial (NEST-2) was a prospective, double-blind, randomized and sham (inactive procedure) controlled study of the safety and effectiveness of a device called the NeuroThera® Laser System. NEST-2, which included 660 patients and 53 researchers in four countries, is the largest human trial and the first Phase III (large randomized trial of effectiveness) of transcranial laser therapy to date. Researchers found: "For a trial that 'failed,' this one was reasonably encouraging," Zivin said, a staff neurologist at the San Diego Veterans Administration (VA) Medical Center. "Laser therapy is unlike most treatments that have been tried for acute stroke."

The only FDA-approved treatment for a stroke caused by a blood clot (an ischemic stroke) is an intravenous clot-busting drug called tissue plasminogen activator or tPA and it must be given within three hours of symptom onset. Other treatments include delivering clot-busters directly to the arteries and mechanical clot removal.

In this trial, the laser was used within 24 hours of stroke onset, with the average time to treatment being 14.6 hours. The device uses low-energy infrared radiation to painlessly penetrate several centimeters into the skull.

"We're not mechanically injuring the brain at all," Zivin said. "We shave off the patient's hair and aim the laser at 20 points around the head so that the beam can cause a reaction in or around the damaged tissue."

While the mechanisms of laser therapy are unknown, earlier animal studies indicated that spacing the laser therapy at 20 points around the skull was more effective that targeting one point. That may be because the 20-point approach allows infrared beams to cover the area of brain damage from many different angles, he said.

In the trial, researchers used two well-known scales to measure laser effectiveness on stroke disability and neurological improvement 90 days after stroke. The modified Rankin Scale (mRS) is a seven-point (0 to 6) scale of stroke disability and dependence in which "0" represents no disability; "1" refers to deficits so slight only a neurologist would notice them; "2" is slight disability such as the inability to conduct previous activities, but able to care for own affairs without assistance; and "6" is death. The mRS was used as the trial endpoint, which is the number of patients in each group who had improved to the 0-2 range on the mRS 90 days after the procedure or sham procedure, he said.

The 42-point National Institutes of Health Stroke Scale (NIHSS) is a simplified neurologic exam that measures stroke-related neurologic deficits such as extremity strength, sensory function, coordination and language ability. A higher number means more impairment.

Earlier studies have shown that stroke patients who score 7 or below on the NIHSS tend to recover to the range of 0 to 2 on the Rankin Scale on their own without any treatment. Here, researchers focused on patients who scored 7 to 22 on the NIHSS when they arrived at the hospital.

Although this study excluded stroke patients who received tPA, Zivin said he hopes to explore combination treatment with laser therapy and tPA in the future, he said.
-end-
Co-authors are Marc Fisher, M.D.; Greg Albers, M.D.; Natan Bornstein, M.D.; Werner Hacke, M.D., Ph.D.; Bjorn Dahlof, M.D., Ph.D.; Robert Lew, Ph.D.; Sanja Ilic, M.D. and Jackson Streeter, M.D. Individual author disclosures can be found on the abstract.

The study was funded by PhotoThera, Inc., the maker of the laser.

Statements and conclusions of study authors that are presented at American Heart Association/American Stroke Association scientific meetings are solely those of the study authors and do not necessarily reflect association policy or position. The association makes no representation or warranty as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events. The association has strict policies to prevent these relationships from influencing science content. Revenues from pharmaceutical and device corporations are available at www.americanheart.org/corporatefunding.

American Heart Association

Related Stroke Articles from Brightsurf:

Stroke alarm clock may streamline and accelerate time-sensitive acute stroke care
An interactive, digital alarm clock may speed emergency stroke care, starting at hospital arrival and through each step of the time-sensitive treatment process.

Stroke patients with COVID-19 have increased inflammation, stroke severity and death
Stroke patients who also have COVID-19 showed increased systemic inflammation, a more serious stroke severity and a much higher rate of death, compared to stroke patients who did not have COVID-19, according a retrospective, observational, cross-sectional study of 60 ischemic stroke patients admitted to UAB Hospital between late March and early May 2020.

'Time is vision' after a stroke
University of Rochester researchers studied stroke patients who experienced vision loss and found that the patients retained some visual abilities immediately after the stroke but these abilities diminished gradually and eventually disappeared permanently after approximately six months.

More stroke awareness, better eating habits may help reduce stroke risk for young adult African-Americans
Young African-Americans are experiencing higher rates of stroke because of health conditions such as high blood pressure, diabetes and obesity, yet their perception of their stroke risk is low.

How to help patients recover after a stroke
The existing approach to brain stimulation for rehabilitation after a stroke does not take into account the diversity of lesions and the individual characteristics of patients' brains.

Kids with headache after stroke might be at risk for another stroke
A new study has found a high incidence of headaches in pediatric stroke survivors and identified a possible association between post-stroke headache and stroke recurrence.

High stroke impact in low- and middle-income countries examined at 11th World Stroke Congress
Less wealthy countries struggle to meet greater need with far fewer resources.

Marijuana use might lead to higher risk of stroke, World Stroke Congress to be told
A five-year study of hospital statistics from the United States shows that the incidence of stroke has risen steadily among marijuana users even though the overall rate of stroke remained constant over the same period.

We need to talk about sexuality after stroke
Stroke survivors and their partners are not adequately supported to deal with changes to their relationships, self-identity, gender roles and intimacy following stroke, according to new research from the University of Sydney.

Standardized stroke protocol can ensure ELVO stroke patients are treated within 60 minutes
A new study shows that developing a standardized stroke protocol of having neurointerventional teams meet suspected emergent large vessel occlusion (ELVO) stroke patients upon their arrival at the hospital achieves a median door-to-recanalization time of less than 60 minutes.

Read More: Stroke News and Stroke Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.